Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW685698X in Seasonal Allergic Rhinitis
NCT00115622Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2004
- Primary completion
- Jan 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing GW685698X with Placebo (2 arms). Primary endpoints: Mean change from baseline in daily, reflective, total nasal symptom scores at 14 days and Mean change from baseline in daily, reflective, total ocular symptom score at 14 days. Started Dec 2004; status: completed.
02
Drugs
fluticasone
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00115622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115622.